Top

Published in:

01-09-2015 | Original Scientific Report

National Comprehensive Cancer Network Resectability Status for Pancreatic Carcinoma Predicts Overall Survival

Authors: Yoshiaki Murakami, Sohei Satoi, Masayuki Sho, Fuyuhiko Motoi, Ippei Matsumoto, Manabu Kawai, Goro Honda, Kenichiro Uemura, Hiroaki Yanagimoto, Makoto Shinzeki, Masanao Kurata, Shoichi Kinoshita, Hiroki Yamaue, Michiaki Unno

Published in: World Journal of Surgery | Issue 9/2015

Abstract

Background

The aim of this study was to evaluate the validity of preoperative resectability status, as defined by the National Comprehensive Cancer Network (NCCN), from the viewpoint of overall survival.

Methods

A total of consecutive 704 patients with pancreatic head carcinoma who underwent pancreatoduodenectomy with upfront surgery at seven Japanese hospitals between 2001 and 2012 were evaluated retrospectively. According to the NCCN definition of preoperative resectability status, tumors were divided into resectable tumors without vascular contact (R group), resectable tumors with portal or superior mesenteric vein (PV/SMV) contact of ≦180° (R-PV group), borderline resectable(BR) tumors with PV/SMV contact of >180° (BR-PV group), and BR tumors with arterial contact (BR-A group). The relationship between the NCCN definition of preoperative resectability status and overall survival was analyzed.

Results

Of the 704 patients, 389, 114, 145, and 56 were classified into the R group, the R-PV group, the BR-PV group, and the BR-A group, respectively. Overall survival of the BR-PV and BR-A groups was significantly worse than that of the R group and R-PV groups (P < 0.05), although there was no significant difference in overall survival between the R group and the R-PV group (P = 0.310). Multivariate analysis revealed that PV/SMV contact of >180° (P = 0.008) and arterial contact (P < 0.001) were independent prognostic factors of overall survival.

Conclusion

From the viewpoint of overall survival, the NCCN definition of preoperative resectability status was valid.

Siegel R, Ma J, Zou Z (2014) Cancer statistics, 2014. CA Cancer J Clin 64:9–29PubMedCrossRef

National Comprehensive Cancer Network NCCN clinical practice guidelines in oncology. Pancreatic adenocarcinoma, version 1 2015 edn (2015). http://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf

Callery MP, Chang KJ, Fishman EK et al (2009) Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Ann Surg Oncol 16:1727–1733PubMedCrossRef

Katz MH, Pisters PW, Evans DB et al (2008) Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg 206:833–846PubMedCrossRef

Bockhorn M, Uzunoglu FG, Adham M et al; International Study Group of Pancreatic Surgery (2014) Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS). Surgery 155:977–988CrossRef

Takahashi S, Kinoshita T, Konishi M et al (2011) Borderline resectable pancreatic cancer: rationale for multidisciplinary treatment. J Hepatobiliary Pancreat Sci 18:567–574PubMedCrossRef

Yamada S, Fujii T, Sugimoto H et al (2013) Aggressive surgery for borderline resectable pancreatic cancer: evaluation of National Comprehensive Cancer Network guidelines. Pancreas 42:1004–1010PubMedCrossRef

Miura JT, Evans DB, Pappas SG et al (2013) Borderline resectable/locally advanced pancreatic adenocarcinoma: improvements needed in population-based registries. Ann Surg Oncol 20:4338–4347PubMedCrossRef

Kato H, Usui M, Isaji S et al (2013) Clinical features and treatment outcome of borderline resectable pancreatic head/body cancer: a multi-institutional survey by the Japanese Society of Pancreatic Surgery. J Hepatobiliary Pancreat Sci 20(6):601–610PubMedCrossRef

10.

Murakami Y, Uemura K, Sudo T et al (2013) Benefit of portal or superior mesenteric vein resection with adjuvant chemotherapy for patients with pancreatic head carcinoma. J Surg Oncol 107:414–421PubMedCrossRef

11.

Kaneoka Y, Yamaguchi A, Isogai M (2009) Portal or superior mesenteric vein resection for pancreatic head adenocarcinoma: prognostic value of the length of venous resection. Surgery 145:417–425PubMedCrossRef

12.

Shimada K, Sano T, Sakamoto Y et al (2006) Clinical implications of combined portal vein resection as a palliative procedure in patients undergoing pancreaticoduodenectomy for pancreatic head carcinoma. Ann Surg Oncol 13:1569–1578PubMedCrossRef

13.

Nakao A, Takeda S, Inoue S et al (2006) Indications and techniques of extended resection for pancreatic cancer. World J Surg 30:976–982. doi:10.1007/s00268-005-0438-6 PubMedCrossRef

14.

Murakami Y, Uemura K, Sudo T et al (2012) Long-term results of adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for pancreatic carcinoma. J Surg Oncol 106:174–180PubMedCrossRef

15.

Sobin LH, Gospodarowicz MK, Wittekind C (eds) (2010) International Union Against Cancer (UICC): TNM classification of malignant tumors, 7th edn. Wiley-Blackwell, New York

16.

Bassi C, Dervenis C, Butturini G et al; International Study Group on Pancreatic Fistula Definition (2005) Postoperative pancreatic fistula: an international study group (ISGPF) definition. Surgery 138:8–13CrossRef

17.

Dindo D, Demartines N, Clavien PA (2004) Classification of surgical complications. A new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240:205–213PubMedCentralPubMedCrossRef

18.

Shinchi H, Maemura K, Mataki Y et al (2012) A phase II study of oral S-1 with concurrent radiotherapy followed by chemotherapy with S-1 alone for locally advanced pancreatic cancer. J Hepatobiliary Pancreat Sci 19:152–158PubMedCrossRef

19.

Sudo K, Yamaguchi T, Ishihara T et al (2012) Phase II study of oral S-1 and concurrent radiotherapy in patients with unresectable locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 80:119–125CrossRef

20.

Ishii H, Furuse J, Boku N et al; JCOG Gastrointestinal Oncology Study Group (2010) Phase II study of gemcitabine chemotherapy alone for locally advanced pancreatic carcinoma: JCOG0506. Jpn J Clin Oncol 40:573–579CrossRef

21.

Lee JL, Kim SC, Kim JH et al (2012) Prospective efficacy and safety study of neoadjuvant gemcitabine with capecitabine combination chemotherapy for borderline-resectable or unresectable locally advanced pancreatic adenocarcinoma. Surgery 152:851–862PubMedCrossRef

22.

Sahora K, Kuehrer I, Eisenhut A et al (2011) NeoGemOx: gemcitabine and oxaliplatin as neoadjuvant treatment for locally advanced, nonmetastasized pancreatic cancer. Surgery 149:311–320PubMedCrossRef

23.

Kim EJ, Ben-Josef E, Herman JM et al (2013) A multi-institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer. Cancer 119:2692–2700PubMedCentralPubMedCrossRef

24.

Katz MH, Fleming JB, Bhosale P et al (2012) Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer 118:5749–5756PubMedCrossRef

25.

Wang J, Estrella JS, Peng L et al (2012) Histologic tumor involvement of superior mesenteric vein/portal vein predicts poor prognosis in patients with stage II pancreatic adenocarcinoma treated with neoadjuvant chemoradiation. Cancer 118:3801–3811PubMedCentralPubMedCrossRef

Title: National Comprehensive Cancer Network Resectability Status for Pancreatic Carcinoma Predicts Overall Survival
Authors: Yoshiaki Murakami
Sohei Satoi
Masayuki Sho
Fuyuhiko Motoi
Ippei Matsumoto
Manabu Kawai
Goro Honda
Kenichiro Uemura
Hiroaki Yanagimoto
Makoto Shinzeki
Masanao Kurata
Shoichi Kinoshita
Hiroki Yamaue
Michiaki Unno
Publication date: 01-09-2015
Publisher: Springer International Publishing
Published in: World Journal of Surgery / Issue 9/2015
Print ISSN: 0364-2313
Electronic ISSN: 1432-2323
DOI: https://doi.org/10.1007/s00268-015-3096-3

At a glance: The STEP trials

Springer Medicine

National Comprehensive Cancer Network Resectability Status for Pancreatic Carcinoma Predicts Overall Survival

Abstract

Background

Methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 9/2015

Naso-enteric Tube Placement: A Review of Methods to Confirm Tip Location, Global Applicability and Requirements

Quantifying the Disability from Congenital Anomalies Averted Through Pediatric Surgery: A Cross-Sectional Comparison of a Pediatric Surgical Unit in Kenya and Canada

Preoperative Platelet–Lymphocyte Ratio Augments CA 19-9 as a Predictor of Malignancy in Chronic Calcific Pancreatitis

A Banner Year for Global Surgery: Now How to Make it Make a Difference on the Ground

Quality of Life After Living Donor Hepatectomy for Liver Transplantation

Screening Men with Coronary Heart Disease for Abdominal Aortic Aneurysm: A Prospective Cohort Study